We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week
Published in Oncology

Journal Scan / Research · September 28, 2022

Long-Term Overall Survival Outcomes of Maintenance Olaparib in Patients With Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation

Journal of Clinical Oncology


Additional Info

Journal of Clinical Oncology
Overall Survival With Maintenance Olaparib at a 7-Year Follow-Up in Patients With Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1/GOG 3004 Trial
J. Clin. Oncol 2022 Sep 09;[EPub Ahead of Print], P DiSilvestro, S Banerjee, N Colombo, G Scambia, BG Kim, A Oaknin, M Friedlander, A Lisyanskaya, A Floquet, A Leary, GS Sonke, C Gourley, A Oza, A González-Martín, C Aghajanian, W Bradley, C Mathews, J Liu, J McNamara, ES Lowe, ML Ah-See, KN Moore

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading